Table 3 Univariate and multivariate analysis of iPFS in patients with LM (n = 62).

From: Furmonertinib combined with bevacizumab in EGFR-TKI-resistant leptomeningeal metastasis: analysis of the CSF ctDNA molecular response and survival outcomes

Variables

Univariate

Multivariate

HR (95% CI)

P

HR (95% CI)

P

Age (<60 vs. ≥60 years)

0.662 (0.384–1.141)

0.138

  

Sex (male vs. female)

0.815 (0.475–1.399)

0.459

  

TP53 mutation in CSF

0.865 (0.494–1.517)

0.613

  

(yes vs. no)

Smoking status (yes vs. no)

0.995 (0.524–1.892)

0.988

  

ECOG PS (2 vs.3–4)

0.455 (0.257–0.805)

0.007

0.453 (0.255–0.805)

0.007

Concurrent brain metastases

1.274 (0.754–2.154)

0.366

  

Concurrent bone metastases

1.728 (0.952–3.139)

0.072

  

Treatment lines (≤3 vs. >3)

1.098 (0.649–1.857)

0.728

  

Treatments of LM

WBRT (yes vs. no)

0.944 (0.539–1.653)

0.839

  

Intrathecal chemotherapy

0.335 (0.171–0.659)

0.002

0.335 (0.170–0.660)

0.002

(yes vs. no)

  1. iPFS intracranial progression-free survival, LM leptomeningeal metastasis, HR hazard ratio, CI confidence interval, TP53 tumour protein p53 gene, CSF cerebrospinal fluid, ECOG PS Eastern Cooperative Oncology Group Performance Status, WBRT whole-brain radiotherapy.
Back to article page